Cancer Family
Genitourinary System Neoplasm
CI-CAN-00000018Explore in graph →
Non-malignant3,846 active trials61 approved drugs306 evidence items
- NCIt
- C156482
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000018Explore in graph →
Variants & evidence
684 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| BRCA1 Mutation4 | ||||||||
| Rucaparib | Malignant Ovarian Neoplasm | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID1897A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian, fallopian tube or primary peritoneal carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor rucaparib… (full text at CIViC) PMID 27908594 · Swisher et al., 2017 · Open in CIViC | civic |
| 〃 | Malignant Ovarian Neoplasm | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID6341A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian, fallopian tube or primary peritoneal carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor rucaparib… (full text at CIViC) PMID 27908594 · Swisher et al., 2017 · Open in CIViC | civic |
| 〃 | Castration-Resistant Prostate Carcinoma | Predictive | B | Does Not Support Sensitivity Response | 3 | submitted | EID13266In a prespecified subgroup analysis of the randomized phase III TRITON3 trial, patients with metastatic castration-resistant prostate cancer harboring germline or somatic deleterious BRCA1 alterations… (full text at CIViC) PMID 36795891 · Fizazi et al., 2023 · Open in CIViC | civic |
| Enzalutamide + TalazoparibCombination | Castration-Resistant Prostate Carcinoma | Predictive | A | Supports Sensitivity Response | 2 | submitted | EID11734This phase 3 study evaluated the PARP inhibitor talazoparib in combination with the androgen receptor inhibitor enzalutamide as a first-line treatment in patients with metastatic castration-resistant… (full text at CIViC) PMID 38049622 · Fizazi et al., 2024 · Open in CIViC | civic |
| BRCA1 Mutation + BRCA2 MutationBRCA2BRCA18 | ||||||||
| Olaparib | Malignant Prostate Neoplasm | Predictive | A | Supports Sensitivity Response | 4 | submitted | EID12941In the BRCA‑altered cohort (n = 160; BRCA1/2 alterations) of the global, randomized, open‑label phase III PROfound trial (NCT02987543) in metastatic castration‑resistant prostate cancer (mCRPC), patie… (full text at CIViC) PMID 37963304 · Mateo et al., 2024 · Open in CIViC | civic |
| Rucaparib | Malignant Prostate Neoplasm | Predictive | A | Supports Sensitivity Response | 4 | rejected | EID11245In an open-label, phase 2 study, 115 male patients with castration-resistant prostate cancer and a BRCA1/2 alteration with or without measurable disease were enrolled to receive rucaparib 600 mg twice… (full text at CIViC) PMID 32795228 · Abida et al., 2020 · Open in CIViC | civic |
| Niraparib | Ovarian CarcinomaALIAS | |||||||
| BRCA1 P968FS1 | ||||||||
| (predisposing) | Malignant Ovarian Neoplasm | Predisposing | C | Supports Predisposition | 4 | accepted | EID1124A 55-year-old non-Ashkenazi Spanish female diagnosed with breast cancer (at 51 years old) and ovarian cancer. Sequencing of BRCA1 and BRCA2 revealed a 2-base frameshift insertion in BRCA1 (labeled 302… (full text at CIViC) PMID 24137399 · Salgado et al., 2013 · Open in CIViC | civic |
| BRCA1 Q1467*1 | ||||||||
| Rucaparib | Malignant Ovarian Neoplasm | Predictive | C | Supports Sensitivity Response | — | accepted | EID2878In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression … (full text at CIViC) PMID 27908594 · Swisher et al., 2017 · Open in CIViC | civic |
| BRCA1 Underexpression1 | ||||||||
| Platinum Compound + Taxane CompoundCombination | Malignant Ovarian Neoplasm | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID942Absent/low expression of BRCA1 (IHC) was associated with improved response to chemotherapy in 292 patients with sporadic ovarian cancer compared to patients with high expression (odds ratio 2.47: 95%C… (full text at CIViC) PMID 21920589 · Carser et al., 2011 · Open in CIViC | civic |
| BRCA1 W1815X1 | ||||||||
| Olaparib | Ovarian Endometrioid AdenocarcinomaALIAS | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID4623In an in vitro study, a SNU-251 cell line expressing BRCA1 W1815X truncating mutation demonstrated increased sensitivity to olaparib treatment with long-term exposure, compared to ovarian cell lines e… (full text at CIViC) PMID 23415752 · Stordal et al., 2013 · Open in CIViC | civic |
| BRCA2 Loss-of-function8 | ||||||||
| (prognostic) | Malignant Prostate Neoplasm | Prognostic | B | Supports Poor Outcome | 3 | accepted | EID1524In a study of 2,019 patients with prostate cancer, 18 had germ-line BRCA1 mutations, 61 had germ-line BRCA2 mutations and 1,940 were non-carriers. Patients with BRCA1/2 mutations had a 2-fold higher … (full text at CIViC) PMID 23569316 · Castro et al., 2013 · Open in CIViC | civic |
| Cisplatin + DasatinibCombination | Malignant Prostate Neoplasm | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID8981Transcriptomic analysis of BRCA2-null metastatic castration-resistant prostate cancers revealed activation of the SRC signaling pathway. Platinum-based chemotherapies have shown efficacy in BRCA2-alte… (full text at CIViC) PMID 33334906 · Chakraborty et al., 2021 · Open in CIViC | civic |
| Dasatinib + TalazoparibCombination | Malignant Prostate Neoplasm | |||||||
| BRCA2 M1?1 | ||||||||
| Rucaparib | Malignant Ovarian Neoplasm | Predictive | C | Supports Sensitivity Response | — | accepted | EID2880In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression … (full text at CIViC) PMID 27908594 · Swisher et al., 2017 · Open in CIViC | civic |
| BRCA2 M1R1 | ||||||||
| Rucaparib | Malignant Ovarian Neoplasm | Predictive | C | Supports Sensitivity Response | — | accepted | EID2879In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression … (full text at CIViC) PMID 27908594 · Swisher et al., 2017 · Open in CIViC | civic |
| BRCA2 Mutation19 | ||||||||
| (prognostic) | Ovarian CarcinomaALIAS | Prognostic | B | Supports Better Outcome | 3 | accepted | EID465In patients with invasive epithelial ovarian cancer, those with mutations in BRCA2 had better five-year overall survival. PMID 22274685 · Bolton et al., 2012 · Open in CIViC | civic |
| 〃 | Malignant Ovarian Neoplasm | Prognostic | B | Supports Better Outcome | 3 | accepted | EID1676664 patients with non-bulky FIGO Stage II-IV ovarian cancer were evaluated for PFS when treated with Pazopanib versus placebo. Of the 664 patients, 10% (n=68) were BRCA1+, 4% were BRCA 2+ (n=29) and … (full text at CIViC) PMID 26740259 · Harter et al., 2016 · Open in CIViC | civic |
| Olaparib | Malignant Ovarian Neoplasm | Predictive | A | Supports Sensitivity Response | 5 | |||
| BRCA2 R2336P1 | ||||||||
| Rucaparib | Malignant Ovarian Neoplasm | Predictive | C | Supports Sensitivity Response | — | accepted | EID2884In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression … (full text at CIViC) PMID 27908594 · Swisher et al., 2017 · Open in CIViC | civic |
| BRCA2 V159M1 | ||||||||
| Rucaparib | Malignant Ovarian Neoplasm | Predictive | C | Supports Sensitivity Response | — | accepted | EID2881In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression … (full text at CIViC) PMID 27908594 · Swisher et al., 2017 · Open in CIViC | civic |
| BRCA2 V211I1 | ||||||||
| Rucaparib | Malignant Ovarian Neoplasm | Predictive | C | Supports Sensitivity Response | 4 | accepted | EID2883In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression … (full text at CIViC) PMID 27908594 · Swisher et al., 2017 · Open in CIViC | civic |
| BRCA2 V211L1 | ||||||||
| Rucaparib | Malignant Ovarian Neoplasm | Predictive | C | Supports Sensitivity Response | — | accepted | EID2882In a phase 2 study of 206 recurrent, platinum-sensitive, high-grade ovarian cancer patients, patients with germline or somatic BRCA1 or BRCA2 mutation (n=40) were associated with improved progression … (full text at CIViC) PMID 27908594 · Swisher et al., 2017 · Open in CIViC | civic |
| BRD4 Overexpression1 | ||||||||
| JQ1 | Clear Cell Renal Cell Carcinoma | Predictive | D | Supports Sensitivity Response | 2 | submitted | EID2957Renal cell carcinoma (RCC) remains an intractable genitourinary malignancy. Resistance to chemotherapy or targeted therapies in RCC is presumably due to the complicated underlying molecular mechanisms… (full text at CIViC) PMID 28391274 · Wu et al., 2017 · Open in CIViC | civic |
Data updated 22 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.
| Predictive |
| A |
| Supports Sensitivity Response |
| 4 |
| accepted |
EID11243In a randomized, double-blind, phase 3 trial, 553 patients with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with predominantly high-grade serous histologic features were enroll… (full text at CIViC) PMID 27717299 · Mirza et al., 2016 · Open in CIViC |
| civic |
| 〃 | Fallopian Tube Carcinoma | Predictive | A | Supports Sensitivity Response | 4 | submitted | EID11305In a randomized, double-blind, phase 3 trial, 553 patients with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with predominantly high-grade serous histologic features were enroll… (full text at CIViC) PMID 27717299 · Mirza et al., 2016 · Open in CIViC | civic |
| Abiraterone + NiraparibCombination | Castration-Resistant Prostate Carcinoma | Predictive | A | Supports Sensitivity Response | 4 | submitted | EID11738A phase 3 trial (NCT03748641) evaluated the clinical benefit of the PARP inhibitor niraparib in combination with abiraterone acetate plus prednisone (AAP) in metastatic castration-resistant prostate … (full text at CIViC) PMID 36952634 · Chi et al., 2023 · Open in CIViC | civic |
| Olaparib | Malignant Prostate Neoplasm | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID11666A clinical study was conducted in 30 patients with Metastatic Prostate Cancer harboring BRCA1/2 mutations treated with olaparib. A disease control rate of 69% (95% CI, 51-81) and an objective response… (full text at CIViC) PMID 36753688 · Yang et al., 2023 · Open in CIViC | civic |
| 〃 | Malignant Uterine NeoplasmALIAS | Predictive | B | Supports Sensitivity Response | 2 | accepted | EID12766In the uterine carcinoma cohort of the phase II TAPUR trial (NCT02693535), PRs were observed in 3 of 15 evaluable patients with BRCA1 (n = 2) or BRCA2 (n = 1) alterations, with response durations of 8… (full text at CIViC) PMID 41100773 · Al Baghdadi et al., 2025 · Open in CIViC | civic |
| Rucaparib | Castration-Resistant Prostate Carcinoma | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID12944In the BRCA-altered cohort (n = 302; deleterious BRCA1/2 alterations) of the global, randomized, open-label phase III TRITON3 trial (NCT02975934) in mCRPC, pts treated with rucaparib (600 mg twice/day… (full text at CIViC) PMID 36795891 · Fizazi et al., 2023 · Open in CIViC | civic |
| Predictive |
| D |
| Supports Sensitivity Response |
| 4 |
| submitted |
EID8980Transcriptomic analysis of BRCA2-null metastatic castration-resistant prostate cancers revealed activation of the SRC signaling pathway, which may be related to PARP inhibitor resistance. Preclinical … (full text at CIViC) PMID 33334906 · Chakraborty et al., 2021 · Open in CIViC |
| civic |
| Olaparib | Malignant Ovarian Neoplasm | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID212The combination of PARP inhibition (Olaparib) with BRCA mutation results in irreparable and lethal DNA damage. Response rates are higher in BRCA2 mutation positive women with high grade serous or undi… (full text at CIViC) PMID 23346317 · Goff, 2013 · Open in CIViC | civic |
| 〃 | Malignant Prostate Neoplasm | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID650In a phase 2 trial of patients with metastatic, castration-resistant prostate cancer, treated with olaparib tablets at a dose of 400 mg twice a day, all 7 patients harbouring BRCA2 loss of function al… (full text at CIViC) PMID 26510020 · Mateo et al., 2015 · Open in CIViC | civic |
| Dasatinib + OlaparibCombination | Malignant Prostate Neoplasm | Predictive | D | Supports Sensitivity Response | 4 | submitted | EID8979Transcriptomic analysis of BRCA2-null metastatic castration-resistant prostate cancers revealed activation of the SRC signaling pathway, which may be related to PARP inhibitor resistance. Preclinical … (full text at CIViC) PMID 33334906 · Chakraborty et al., 2021 · Open in CIViC | civic |
| Talazoparib | Malignant Ovarian Neoplasm | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID4875In part 2 of a two-part dose-escalation phase I trial (NCT01286987), 71 patients with Ewings sarcoma, breast, ovarian, small cell lung, or pancreatic cancers received 1.0 mg/day talazoparib treatment.… (full text at CIViC) PMID 28242752 · de Bono et al., 2017 · Open in CIViC | civic |
| Bosutinib + TalazoparibCombination | Malignant Prostate Neoplasm | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID8982Transcriptomic analysis of BRCA2-null metastatic castration-resistant prostate cancers revealed activation of the SRC signaling pathway, which may be related to PARP inhibitor resistance. Preclinical … (full text at CIViC) PMID 33334906 · Chakraborty et al., 2021 · Open in CIViC | civic |
EID7276In the phase 3 SOLO1 trial 390 patients with newly diagnosed advanced ovarian cancer with a mutation in BRCA1 or BRCA2 who had complete or partial response after platinum-based chemotherapy were rando… (full text at CIViC) PMID 30345884 · Moore et al., 2018 · Open in CIViC |
| civic |
| 〃 | Castration-Resistant Prostate Carcinoma | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID8842In phase 3 trial of 387 patients comparing olaparib and new hormonal agent (enzalutamide or abiraterone) therapy for patients with metastatic castration-resistant prostate cancer harboring homologous … (full text at CIViC) PMID 32343890 · de Bono et al., 2020 · Open in CIViC | civic |
| 〃 | Malignant Prostate Neoplasm | Predictive | A | Supports Sensitivity Response | 4 | submitted | EID12942In the post hoc exploratory BRCA2-only subgroup (n = 128; olaparib, n = 81; control, n = 47) of the phase III randomized open-label PROfound trial (NCT02987543), olaparib monotherapy supported Sensiti… (full text at CIViC) PMID 37963304 · Mateo et al., 2024 · Open in CIViC | civic |
| 〃 | Ovarian Serous AdenocarcinomaALIAS | Predictive | B | Supports Sensitivity Response | 4 | submitted | EID6334In patients with platinum-sensitive, recurrent serous ovarian cancer with BRCA mutation, median PFS was significantly longer in patients that received olaparib as compared to placebo (11.2 vs. 4.3 mon… (full text at CIViC) PMID 24882434 · Ledermann et al., 2014 · Open in CIViC | civic |
| 〃 | Malignant Prostate Neoplasm | Predictive | B | Supports Sensitivity Response | 4 | submitted | EID7471In a phase 2 trial, patients with metastatic castration-resistant prostate cancer harboring DNA damage repair (DDR) gene aberrations were treated with olaparib. In gene testing, samples from tumor tis… (full text at CIViC) | civic |
| 〃 | Malignant Ovarian Neoplasm | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID1773In a study of 63 patients with ovarian cancer, 17 patients had BRCA1 or BRCA2 mutations and 46 patients had no BRCA mutations. Of the BRCA-positive patients, 7/17(41%; 95%CI 22-64) showed objective r… (full text at CIViC) PMID 21862407 · Gelmon et al., 2011 · Open in CIViC | civic |
| 〃 | Malignant Prostate Neoplasm | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID7457In a retrospective study, 23 consecutive patients with prostate cancer harboring germline BRCA1/2 or ATM mutations were treated with olaparib were reviewed. This study included 2 patients with BRCA1 m… (full text at CIViC) PMID 30797618 · Marshall et al., 2019 · Open in CIViC | civic |
| 〃 | Malignant Ovarian Neoplasm | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID11426The article detailed a phase III trial (SOLO3) of olaparib tablets versus nonplatinum chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer who had received at… (full text at CIViC) PMID 32073956 · Penson et al., 2020 · Open in CIViC | civic |
| Cediranib + OlaparibCombination | Malignant Ovarian Neoplasm | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID167846 women with platinum-sensitive, high-grade, BRCA1/2+ ovarian cancer received either olaparib monotherapy or olaparib/cediranib combination therapy. Median PFS was increased in combination therapy (… (full text at CIViC) PMID 25218906 · Liu et al., 2014 · Open in CIViC | civic |
| Platinum Compound | Ovarian Carcinoma | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID1530In a study of ovarian carcinomas, 81% of tumors with germline BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=47; N=158; P=0… (full text at CIViC) PMID 24240112 · Pennington et al., 2014 · Open in CIViC | civic |
| 〃 | Ovarian Carcinoma | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID1532In a study of ovarian carcinomas, 87% of tumors with somatic BRCA1/2 mutations were platinum sensitive, whereas only 60% of tumors with non-BRCA1/2 mutations were platinum sensitive (N=38; N=158; P=0.… (full text at CIViC) PMID 24240112 · Pennington et al., 2014 · Open in CIViC | civic |
| Rucaparib | Malignant Ovarian Neoplasm | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID11137Combined meta-analysis of Study 10 (NCT01482715, phase I/II) and ARIEL2 (NCT01891344, phase II), both multi-centre, open-label, single-arm trials evaluating rucaparib in ovarian cancer with BRCA1 or B… (full text at CIViC) PMID 28882436 · Oza et al., 2017 · Open in CIViC | civic |
| 〃 | Malignant Ovarian Neoplasm | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID11139Combined meta-analysis of Study 10 (NCT01482715, phase I/II) and ARIEL2 (NCT01891344, phase II), both multi-centre, open-label, single-arm trials evaluating rucaparib in ovarian cancer with BRCA1 or B… (full text at CIViC) PMID 28882436 · Oza et al., 2017 · Open in CIViC | civic |
| 〃 | Castration-Resistant Prostate Carcinoma | Predictive | B | Supports Sensitivity Response | 4 | submitted | EID13267In a prespecified subgroup analysis of the randomized phase III TRITON3 trial, patients with metastatic castration-resistant prostate cancer harboring germline or somatic deleterious BRCA2 alterations… (full text at CIViC) PMID 36795891 · Fizazi et al., 2023 · Open in CIViC | civic |
| 〃 | Malignant Ovarian Neoplasm | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID6343A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian, fallopian tube or primary peritoneal carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor rucaparib… (full text at CIViC) PMID 27908594 · Swisher et al., 2017 · Open in CIViC | civic |
| 〃 | Malignant Ovarian Neoplasm | Predictive | B | Supports Sensitivity Response | 2 | accepted | EID2868A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian, fallopian tube or primary peritoneal carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor rucaparib… (full text at CIViC) PMID 27908594 · Swisher et al., 2017 · Open in CIViC | civic |
| Enzalutamide + TalazoparibCombination | Castration-Resistant Prostate Carcinoma | Predictive | A | Supports Sensitivity Response | 4 | submitted | EID11733This phase 3 study evaluated the PARP inhibitor talazoparib in combination with the androgen receptor inhibitor enzalutamide as a first-line treatment in patients with metastatic castration-resistant… (full text at CIViC) PMID 38049622 · Fizazi et al., 2024 · Open in CIViC | civic |